



TABLE OF CONTENTS

Chapter 1.....	1
1.1. Introduction.....	2
1.2. Research envisaged.....	6
1.3. References.....	8
Chapter 2.....	11
2.1 Pain.....	12
2.2. Migraine.....	15
2.3 Drug Delivery to the Central Nervous System.....	21
2.3.1. Barriers to CNS deliver.....	21
2.3.2. Strategies for Enhanced CNS Drug Delivery.....	26
2.4. Intranasal drug deliver for brain targeting.....	30
2.4.1. Nasal Anatomy and Physiology.....	32
2.4.2. Mechanism of Nose to Brain Drug Transport.....	34
2.4.3 Factors Affecting Brain-Targeted Nasal Delivery Systems.....	37
2.4.4. Nasal Dosage Forms.....	43
2.4.5. Animal Models for Evaluation of Nasal Drug Absorption Studies.....	44
2.5. Novel nasal delivery systems.....	47
2.5.1. Chitosan.....	47
2.5.2. Thiolated Chitosans: Novel Polymers for Mucoadhesive Drug Delivery.....	55
2.5.3. Trimethyl chitosan and its applications in drug delivery.....	65
2.6. Drug profile.....	77
2.6.1 Tizanidine HCl.....	77
2.6.2 Cyclobenzaprine HCl.....	80
2.7. References.....	84
Chapter 3.....	95
3.1. Introduction.....	96
3.1.1. Materials and Equipments.....	96
3.2. Estimation of Tizanidine HCl and Cyclobenzaprine HCl by U.V. spectroscopy method.....	97
3.2.1. Estimation of Tizanidine HCl in distilled water.....	97
3.2.2. Estimation of Tizanidine HCl in Phosphate buffer (pH 5).....	99
3.2.3. Estimation of Cyclobenzaprine HCl in distilled water.....	100
3.2.4. Estimation of Cyclobenzaprine HCl in phosphate buffer (pH 5).....	102
3.3. Estimation of Tizanidine HCl and Cyclobenzaprine HCl by High Performance Liquid Chromatography (HPLC) method.....	104
3.3.1. Estimation of Tizanidine HCl in solution.....	104
3.3.2. Estimation of Cyclobenzaprine HCl in solution.....	106
3.4. Estimation of Rhodamine B by U.V. method.....	108
3.4.1. Estimation of Rhodamine B in distilled water.....	108
3.5. Estimation of Tizanidine HCl and Cyclobenzaprine HCl in NPs.....	110
3.6. Estimation of Tizanidine HCl and Cyclobenzaprine HCl for <i>in-vitro</i> release.....	110
3.7. Determination of Particle Size, Polydispersity and Zeta potential.....	111
3.8. Morphological characterization.....	111
3.9. Results and discussion.....	111

3.10. Conclusions.....	112
3.11. References.....	112
Chapter 4.....	114
4.1. Preparation of thiolated chitosan.....	115
4.2. Characterization of thiolated chitosan.....	116
4.2.1. Procedure for Quantitating Sulfhydryl Groups Based on Molar Absorptivity (Ellman's method).....	116
4.2.2. Infrared spectra of NPs.....	117
4.2.3. Mucoadhesion by mucin particle method.....	117
4.3. Results and discussion.....	117
4.3.1. Preparation of thiolated chitosan.....	117
4.3.2. Characterization of thiolated chitosan.....	118
4.3.2.1. Procedure for Quantitating Sulfhydryl Groups Based on Molar Absorptivity (Ellman's method).....	118
4.3.2.2. Infrared spectra.....	118
4.3.2.3. Mucoadhesion by mucin particle method.....	120
4.4. Preparation of Trimethyl chitosan.....	124
4.5. Characterization of trimethyl chitosan.....	124
4.5.1. Infrared spectrum.....	124
4.5.2. ¹ H NMR.....	125
4.5.3. Mucoadhesion by mucin particle method.....	125
4.6. Results and discussion.....	125
4.6.1. Preparation of trimethyl chitosan.....	125
4.6.2. Characterization of trimethyl chitosan.....	126
4.6.2.1. Infrared spectrum.....	126
4.6.2.2. ¹ H NMR.....	128
4.6.2.3. Mucoadhesion by mucin particle method.....	129
4.7. Conclusions.....	132
4.8. References.....	132
Chapter 5.....	135
5.1. Introduction.....	136
5.2. Methods.....	137
5.2.1. Preparation of Tizanidine HCl (TZ) and Cyclobenzaprine HCl (CBZ) loaded chitosan, thiolated chitosan nanoparticles (TC) and trimethyl chitosan (TMC) nanoparticles.....	137
5.2.2 Optimization of Formulation Parameters for chitosan Nanoparticles.....	138
5.2.3. Optimization of Formulation Parameters for Thiolated Chitosan (TC) Nanoparticles.....	155
5.2.4 Optimization of Formulation Parameters for trimethyl chitosan Nanoparticles.....	181
5.3. Lyophilization and optimization of cryoprotectant concentration.....	207
5.4. Preparation of Rhodamine B loaded chitosan, thiolated chitosan and trimethyl chitosan nanoparticles.....	213
5.5. Results and discussion.....	215
5.5.1. Preparation of Tizanidine HCl (TZ) and Cyclobenzaprine HCl (CBZ) loaded chitosan (C), thiolated chitosan (TC) and trimethyl chitosan (TMC) nanoparticles.....	215
5.5.2 Optimization of Formulation Parameters for chitosan Nanoparticles.....	215
5.5.3 Optimization of Formulation Parameters for Thiolated Chitosan (TC) Nanoparticles.....	220

5.5.4. Optimization of Formulation Parameters for Trimethyl chitosan (TMC) Nanoparticles.....	229
5.6. Lyophilization and optimization of cryoprotectant concentration.....	237
5.7. Conclusions.....	238
5.8. References.....	239
Chapter 6.....	242
6.1. Introduction.....	243
6.2. Methods.....	245
6.2.1. Particle size and zeta potential.....	245
6.2.2. Entrapment efficiency.....	245
6.2.3. <i>In-vitro</i> drug release.....	245
6.2.4. Transmission electron microscopy.....	246
6.2.5. Nasal toxicity studies.....	246
6.2.6. Confocal laser scanning microscopy examination.....	246
6.3. Results and Discussions.....	247
6.3.1. Particle size and zeta potential.....	247
6.3.2. Entrapment efficiency.....	258
6.3.3. <i>In-vitro</i> drug release.....	258
6.3.4. Transmission electron microscopy.....	261
6.3.5. Nasal toxicity studies.....	263
6.3.6. Confocal laser scanning microscopy examination.....	265
6.4. Conclusions.....	268
6.5. References.....	268
Chapter 7.....	271
7.1. Introduction.....	272
7.2. Methodology.....	272
7.3. Results and Discussions.....	273
7.4. Conclusions.....	283
7.5. References.....	284
Chapter 8.....	286
8.1. Introduction.....	287
8.2. Methods.....	289
8.2.1. <i>In-vitro</i> cytotoxicity Studies.....	289
8.2.2. Permeability studies of chitosan/thiolated chitosan/trimethyl chitosan NPs using RPMI 2650 cell monolayer.....	290
8.3. Results and discussion.....	292
8.3.1. <i>In-vitro</i> cytotoxicity studies.....	292
8.3.2. TEER measurement and permeation of TZ/CBZ loaded chitosan/thiolated chitosan/trimethyl chitosan NPs.....	298
8.4. Conclusions.....	300
8.5. References.....	300
Chapter 9.....	303
9.1. Introduction.....	304
9.2. Materials.....	306

9.3. Radiolabeling of Tizanidine HCl (TZ) and Cyclobenzaprine HCl (CBZ) formulations and Optimization.....	306
9.4. Biodistribution studies.....	308
9.5. Gamma scintigraphy imaging.....	310
9.6. Statistical analysis.....	310
9.7. Results.....	311
9.7.1. Radiolabeling of Tizanidine HCl (TZ) and Cyclobenzaprine HCl (CBZ) formulations and Optimization.....	311
9.7.2. Biodistribution studies.....	314
9.7.3. Gamma scintigraphy imaging.....	324
9.8. Discussion.....	325
9.8.1. Radiolabeling of Tizanidine HCl (TZ) and Cyclobenzaprine HCl (CBZ) formulations and Optimization.....	325
9.8.2. Biodistribution studies.....	325
9.8.3. Gamma scintigraphy imaging.....	327
9.9. Conclusions.....	328
9.10. References.....	328
Chapter 10.....	330
10. 1. Introduction.....	331
10.2. Animals used.....	332
10.3. Materials.....	332
10.4. Evaluation of N-methyl-D-aspartate (NMDA) induced central hyperalgesia in swiss albino mice for CBZ formulations.....	332
10.5. Evaluation of the antinociceptive effect in swiss albino mice for TZ formulations.....	333
10.6. Data analysis.....	334
10.7. Results and discussions.....	334
10.7.1. Evaluation of N-methyl-D-aspartate (NMDA) induced central hyperalgesia in swiss albino mice for CBZ formulations.....	334
10.7.2. Evaluation of the antinociceptive effect in swiss albino mice for TZ formulations.....	335
10.8. Conclusions.....	336
10.9. References.....	336
Chapter 11.....	339
11.1. Summary.....	340
11.2. Conclusions.....	359